Skip Navigation

JNCI Journal of the National Cancer Institute 1999 91(2):108-109; doi:10.1093/jnci/91.2.108
© 1999 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Roemer, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Roemer, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 91, No. 2, 108-109, January 20, 1999
© 1999 Oxford University Press

NEWS

Thanks, but No Thanks: Breast Cancer Group Declines Funding

Jennifer Roemer

Could the mission of a non-profit breast cancer organization be compromised by a donation from the manufacturer of a cancer treatment drug or detection device? Members of Breast Cancer Action, a San Francisco-based national advocacy group, think so.

In a maverick move among national breast cancer organizations, BCA recently enacted a policy that prohibits it from accepting donations from companies that potentially contribute to or profit from cancer incidence.

The policy, adopted in August 1998 and first published in the group's October/November 1998 newsletter, defines as unacceptable contributions from pharmaceutical, chemical, oil, and tobacco . . . [Full Text of this Article]

No False Claims


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?